Zydus Lifesciences stock gains on launch of Zyrifa for cancer patientsZydus Lifesciences stock gains on launch of Zyrifa for cancer patients

Introduction

Leading healthcare company launched a Denosumab 120 mg biosimilar in India to prevent skeletal complications in cancer patients and support bone health across multiple solid tumors and blood cancers.

Also Read: Fujiyama Power Systems gains 4% after reporting 97.4%  PAT and strong revenue in Q2 FY26

Share price movement of Zydus

On December 10, 2025, Zydus Lifesciences Ltd opened at ₹934.45, up 1.56% from its previous close of ₹919.90. The stock reached a high of ₹937.00 (1.85%) and a low of ₹923.50 (-0.71%). By 3:21 PM, it traded at ₹924.10, a 0.46% increase, with a full market cap of ₹92,986.08 crore.

Zydus Launches Denosumab Biosimilar ‘Zyrifa’

Zydus Lifesciences Ltd launched ‘Zyrifa’, a Denosumab 120 mg subcutaneous biosimilar in India. The therapy targets bone health and aims to reduce skeletal-related events in cancer patients.

Denosumab is a monoclonal antibody used to prevent skeletal complications in patients with osteoporosis and bone metastases from cancers including breast, prostate, lung, kidney, thyroid, myeloma, and head & neck.

Bone metastases affect the spine, pelvis, and ribs, causing pain, fractures, spinal cord compression, reduced mobility, and increased mortality. Advanced breast and prostate cancers show 50-70% bone involvement.

‘Zyrifa’ is priced at Rs 12,495. Zydus Lifesciences continues to expand its biosimilar portfolio for cancer treatment and has partnerships with diagnostic companies for patient care.

Stock performance of Zydus for Period of 1 week, 6 months, and 1 year

Zydus Lifesciences Ltd delivered a -1.57% return over the past week. The stock declined 5.61% over the past six months and fell 5.54% over the past year.

Also Read: PhysicsWallah up 5% with PAT-positive quarter and 26% YoY revenue surge

Shareholding pattern of Zydus

Particulars	Sep 2025	Jun 2025	Mar 2025
Promoter	75.00%	75.00%	75.00%
FII	7.30%	7.10%	7.30%
DII	10.90%	11.10%	11%
Public	6.80%	6.70%	6.70%

About Zydus

Zydus Lifesciences Ltd (NSE: ZYDUSLIFE) is a diversified life-sciences company with leadership in pharmaceuticals and consumer wellness, employing 27,000 people globally, including 1,500 R&D scientists, delivering impactful healthcare solutions.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs